1
项与 Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics) 相关的临床试验A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human) 20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic participants who remain asymptomatic, i.e., who do not develop symptomatic coronavirus disease 2019 (COVID-19) through Day 14 as per the protocol defined criteria.
100 项与 Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics) 相关的临床结果
100 项与 Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics) 相关的转化医学
100 项与 Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics) 相关的专利(医药)
100 项与 Anti-COVID-19 Immune Globulin (Human)(Grifols Therapeutics) 相关的药物交易